Progress on clinical application of bedaquiline
10.3760/cma.j.issn.1674-2397.2022.02.011
- VernacularTitle:贝达喹啉临床应用研究进展
- Author:
Song YANG
1
;
Xiaofeng YAN
;
Shenjie TANG
;
Jianqiong GUO
Author Information
1. 重庆市公共卫生医疗救治中心结核病研究室 400036
- Keywords:
Mycobacterium tuberculosis;
Bedaquiline;
Clinical practice;
Treatment outcomes;
Safety
- From:
Chinese Journal of Clinical Infectious Diseases
2022;15(2):152-160
- CountryChina
- Language:Chinese
-
Abstract:
Drug-resistant tuberculosis (DR-TB) has been a serious global public health problem. There is an urgent need in new drug development for drug-resistant Mycobacterium tuberculosis (MTB). Bedaquiline (Bdq) is a new antituberculous drug belonging to the diarylquinoline class that efficiently inhibits the adenosine triphosphate synthase enzyme of MTB, now is one of the core drugs for the treatment of DR-TB. Bdq can significantly improve the negative rate of sputum culture and reduce the mortality with good safety and tolerance, and it can also shorten the course of treatment for patients with tuberculosis and save costs. This article reviews the efficacy, safety, tolerability and treatment-related issues of Bdq-containing regimens for DR-TB.
